Frequency of occurrence of type 2 diabetes and metabolic disturbances in patients with schizophrenic range disorders with prolonged anti-relapse antipsychotic therapy (based on screening results)
https://doi.org/10.31363/2313-7053-2019-2-37-45
Abstract
The article presents the results of screening data from a simultaneous study of 443 outpatient cards of patients with schizophrenic spectrum disorders who were under dynamic outpatient monitoring in two areas of the psycho-neurological dispensary No. 2 in Moscow in order to assess the incidence of type 2 diabetes mellitus (T2DM), and also metabolic disorders (MD) in patients with prolonged anti-relapse antipsychotic therapy. The incidence of these disorders as a whole was 24.6%. Differences in the prevalence of diabetes mellitus 2 and MN were considered depending on the gender of the patient and the antipsychotic used. The obtained data on the high frequency of occurrence of the above metabolic disorders indicate the need to develop standards for antipsychotic therapy of patients with schizophrenic spectrum disorders when combined with T2DM and MD.
About the Authors
L. N. Gorobets
Moscow Research Institute of Psychiatry, Branch of National Medical Research Center of Psychiatry and Narcology of Health Ministry of Russia
Russian Federation
Moscow
Russian Federation
Moscow
M. A. Tsarenko
Moscow City Psycho-Endocrinological Center
Russian Federation
Moscow
Russian Federation
Moscow
A. V. Litvinov
Moscow Research Institute of Psychiatry, Branch of National Medical Research Center of Psychiatry and Narcology of Health Ministry of Russia
Russian Federation
Moscow
Russian Federation
Moscow
L. M. Vasilenko
Moscow Research Institute of Psychiatry, Branch of National Medical Research Center of Psychiatry and Narcology of Health Ministry of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Alfimov V.P., Ryvkin P.V., Ladyzhenskij M.Ya. i dr. Metabolicheskij sindrom u bol’nyh shizofreniej (obzor literatury) // Sovremennaya terapiya psihicheskih rasstrojstv. 2014. № 3. S. 8-15.
2. Ametov A.S., Bogdanova L.N. Giperglikemiya i glyukozotoksich nost’ — klyuchevye faktory progressirovaniya saharnogo diabeta 2-go tipa // Russkij medicinskij zhurnal. Endokrinologiya. 2010. T. 18, № 23. S. 1416-1422.
3. Gorobets L.N. Nejroehndokrinnye disfunkcii i nejrolepticheskaya terapiya. M.: Medpraktika. 2007. 312 s.
4. Gorobets L.N., Bulanov V.S., Vasilenko L.M., Litvinov A.V., Polyakovskaya T.P. Metabolicheskie rasstrojstva u bol’nyh shizofreniej v processe terapii atipichnymi antipsihoticheskimi preparatami // Zhurnal nevrologii i psihiatrii im. S.S.Korsakova. 2012. Tom 112, №9. S. 90-96.
5. Gorobets L.N., Litvinov A.V., Polyakovskaya T.P. Problemy somaticheskogo zdorov’ya u psihicheski bol’nyh: saharnyj diabet 2 tipa // Social’naya i klinicheskaya psihiatriya. 2013. Tom 23, vypusk 4. S. 62-75.
6. Gorobets L.N., Bulanov V.S., Vasilenko L.M., Litvinov A.V., Ivanova G.P., Polyakovskaya T.P. Nejrolepticheskie metabolicheskie narusheniya pri lechenii antipsihoticheskimi sredstvami novogo pokoleniya // Zhurnal nevrologii i psihiatrii im. S.S.Korsakova. 2014. Tom 114., №2. S. 59-68.
7. Gorobets L.N., Mazo G.Eh. Nejroehndokrinnye disfunkcii pri ispol’zovanii psihofarmakoterapii: klinika, diagnostika, faktory riska i korrekciya // Zhurnal nevrologii i psihiatrii imeni S.S.Korsakova. 2014. Tom 114, №10. S. 122-130.
8. Gorobets L.N., Bulanov V.S., Litvinov A.V. Chastota vstrechaemosti nejroehndokrinnyh disfunkcij u bol’nyh s paranoidnoj shizofreniej v usloviyah ambulatornoj praktiki // Psihiatriya i psihofarmakoterapiya. Zhurnal im. P.B.Gannushkina. 2016. T. 10, №3. S. 27-30.
9. Dedov I.I., Suncov Yu.I., Kudryakova S.V. i soavt. Epidemiologiya insulinonezavisimogo saharnogo diabeta // Problemy ehndokrinologii. 1998. Vyp. 44. S. 45-48.
10. Drobizhev M.Yu. K probleme saharnogo diabeta u bol’nyh shizofreniej (po materialam nekotoryh publikacij v zhurnalah SSHA) // Psihicheskie rasstrojstva v obshchej medicine / Pod red. A.B.Smulevicha. 2007. № 2. S. 35-37.
11. Mazo G.Eh. Perspektivy razvitiya ehndokrinologicheskoj psihiatrii. / Sbornik nauchnyh trudov «Sovremennye dostizheniya v diagnostike i lechenii ehndogennyh psihicheskih rasstrojstv». SPb. 2008. S.210-224.
12. Mazo G.Eh., Shmaneva T.N. Metabolicheskij sindrom u pacientov s depressivnym rasstrojstvom: aktual’noe sostoyanie problemy (obzor literatury) // Obozrenie psihiatrii i medicinskoj psihologii im. V.M.Bekhtereva. 2009. № 4. S. 9-13.
13. Mazo G.Eh., Kibitov A.O. Risk–menedzhment metabolicheskih narushenij pri ispol’zovanii antipsihotikov. // Obozrenie psihiatrii i medicinskoj psihologii im. V.M. Bekhtereva. 2016. №3. S. 98-102.
14. Mosolov S.N., Ryvkin P.V., Serditov O.V. i soavt. Metabolicheskie pobochnye ehffekty sovremennoj antipsihoticheskoj farmakoterapii // Social’naya i klinicheskaya psihiatriya. 2013. T. 23, № 4 73 № 3. S. 75-90.
15. Yastrebov D. I. Metabolicheskie narusheniya pri terapii antipsihoticheskimi preparatami: rekomendacii po diagnostike i podboru terapii (obzor literatury) // Russkij medicinskij zhurnal. 2005. T. 13, №22. S. 35-39.
16. Alberti K.G., Eckel R.H., Grundy S.M. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention // Circulation. 2009. Vol. 120, No 16. P. 1640-1645. doi:10.1161/circulationaha.109.192644
17. Argo T., Carnahan R., Barnett M. et al. Diabetes prevalence estimates in schizophrenia and risk factor assessment // Ann. Clin. Psychiatry. 2011. Vol. 23, N 2. P. 117-124.
18. Chen da C., Zhou M.A., Zhou D.H. et al. Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on longterm antipsychotics // Psychiatry Res. 2011.Vol. 30, N 2-3. P. 451-453. doi: 10.1016/j.psychres.2010.07.054
19. Cimo A., Stergiopoulos E., Cheng C. et al. Effective lifestyle interventions to improve type II diabetes selfmanagement for those with schizophrenia or schizoaffective disorder: a systematic review //BMC Psychiatry. 2012. Vol. 23. Р. 12-24. doi: 10.1186/1471-244x-12-24
20. De Hert M., van Winkel R., van Eyck D. et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study // Clin. Prac. Epidemiol. Ment. Health. 2006. Vol. 2. P. 14. doi: 10.2165/00002018-200629100-00139
21. De Hert M.A., van Winkel R., Van Eyck D. et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication // Schizophr. Res. 2006. Vol. 83, No 1. P. 87-93. doi: 10.1016/j.schres.2005.12.855
22. De Hert M.A., Dekker J.M., Wood D. et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) // Eur. Psychiatry. 2009. Vol. 24, No 6. P. 412-424. doi: 10.1016/j.eurpsy.2009.01.005
23. De Hert M., Mittoux A. et al. Metabolic parameters in the shortand long-term treatment of schizophrenia with sertindole or risperidone // Eur. Arch. Psychiatry Clin. Neurosci. 2010. Р. 5. doi: 10.1007/s00406-010-0142-x
24. Edward K.L., Rasmussen B., Munro I. Nursing care of clients treated with atypical antipsychotics who have a risk of developing metabolic instability and/or type 2 diabetes // Arch. Psychiatr. Nurs. 2010. Vol. 24, N 1. P. 46-53. doi: 10.1016/j.apnu.2009.04.009
25. Feng S., Melkersson K. Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine // Neuro Endocrinol. 2012. Vol. 33, N 5. P. 493-498.
26. Ho C.S., Zhang M.W., Mak A., et al. Metabolic syndrome in psychiatry: advances in understanding and management // Advances in Psychiatric Treatment. 2014. Vol. 20. P. 101-112. doi: 10.1192/apt.bp.113.011619
27. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome // IDF. 2006. 24 p.
28. Koponen H.J., Hakko H.H., Saari K.M. et al. The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study // World J. Biol. Psychiatry. 2010. Vol. 2. P. 262-267. doi: 10.3109/15622970802503334
29. Liao C.H., Chang C.S., Wei W.C. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study // Schizophr. Res. 2011. Vol. 126, N 1–3. P. 110-116. doi: 10.1016/j.schres.2010.12.007
30. McEvoy J.P., Meyer J.M., Goff D.C. et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from CATIE schizophrenia trial and comparison with national estimates from NHANES III // Schizophrenia Res. 2005. Vol. 80. P. 19-32. doi: 10.1016/j.schres.2005.07.014
31. Nasrallah H.A., Meyer J.M., Goff D.C. et al. Low rates for treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline // Schizoph. Res. 2006. Vol. 86. P. 15-22. doi: 10.1016/j.schres.2006.06.026
32. Ramaswamy K., Masand P.S., Nasrallah H.A. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies // Ann. Clin. Psychiatry. 2006. Vol. 18, N 3. P. 183-194. doi: 10.1080/10401230600801234
33. Rethelyi J., Sawalhe A.D. Comorbidity of metabolic syndrome, diabetes and schizophrenia: theoretical and practical considerations // Orv. Hetil. 2011. doi: 10.1556/oh.2011.29079
34. Yogaratnam J., Biswas N., Vadivel R. et al. Metabolic complications of schizophrenia and antipsychotic medications — an updated review // East Asian Arch. Psychiatry. 2013. Vol. 23, N 1. P. 21–28.
35. Zhang R., Hao W., Pan M. The prevalence and clinicaldemographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine // Hum. Psychopharmacol. 2011. Vol. 26, № 6. P. 392– 136. doi: 10.1002/hup.1220
Review
For citations:
Gorobets L.N., Tsarenko M.A., Litvinov A.V., Vasilenko L.M. Frequency of occurrence of type 2 diabetes and metabolic disturbances in patients with schizophrenic range disorders with prolonged anti-relapse antipsychotic therapy (based on screening results). V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2019;(2):37-45. (In Russ.) https://doi.org/10.31363/2313-7053-2019-2-37-45
Views:
717
Email this article 